124499-18-9

Basic information

• Product Name: 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione
• Synonyms: 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione
• CAS NO: 124499-18-9
• Molecular Weight: 330.181
• Mol File: 124499-18-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione(124499-18-9)
• EPA Substance Registry System: 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione(124499-18-9)

Safety Data

• Hazardous Substances Data: 124499-18-9(Hazardous Substances Data)

Upstream product

• 85-44-9 phthalic anhydride 
• 73918-56-6 4-Bromophenethylamine 
• 136918-14-4 phthalimide 
• 4654-39-1 4-bromophenethanol 
• 1122-91-4 4-bromo-benzaldehyde 
• 3156-37-4 4-bromo-β-nitrostyrene 

Downstream Products

• 1377838-26-0 2-(2-(4-(pyrrolidin-1-yl)phenyl)ethyl)isoindoline-1,3-dione 
• 1377838-25-9 2-(4-(piperidin-1-yl)phenethyl)isoindoline-1,3-dione 
• 1377838-27-1 2-(2-(4-(4-methylpiperazin-1-yl)phenyl)ethyl)isoindoline-1,3-dione 
• 308846-03-9 4-[2-(1,3-dioxoisoindolin-2-yl)ethyl]benzonitrile 
• 187283-19-8 tert-butyl N-[[4-(2-aminoethyl)phenyl]methyl]carbamate 
• 794-43-4 2-(2-(4-bromophenyl)-2-oxoethyl)isoindoline-1,3-dione 
• 1595285-39-4 C₆₆H₈₇N₃S₆ 
• 1595285-29-2 C₇₁H₉₁N₃S₄ 
• 663926-22-5 2-(4-(pyrrolidin-1-yl)phenyl)ethanamine 
• 868273-06-7 Org 27569 
• 885229-51-6 2-[2-(4-morpholin-4-ylphenyl)ethyl]-1H-isoindole-1,3(2H)-dione 
• 124498-90-4 (2R,3R,4S,5R)-2-{6-Amino-2-[2-(4-phenethyl-phenyl)-ethylamino]-purin-9-yl}-5-hydroxymethyl-tetrahydro-furan-3,4-diol 

Relevant articles and documents

Stabilization of G-quadruplex DNA, inhibition of telomerase activity, and tumor cell apoptosis by organoplatinum(II) complexes with oxoisoaporphine

Two G-quadruplex ligands [Pt(La)(DMSO)Cl] (Pt1) and [Pt(Lb)(DMSO)Cl] (Pt2) have been synthesized and fully characterized. The two complexes are more selective for SK-OV-3/DDP tumor cells versus normal cells (HL-7702). It was found that both Pt1 and Pt2 could be a telomerase inhibitor targeting G-quadruplex DNA. This is the first report demonstrating that telomeric, c-myc, and bcl-2 G-quadruplexes and caspase-3/9 preferred to bind with Pt2 rather than Pt1, which also can induce senescence and apoptosis. The different biological behavior of Pt1 and Pt2 may correlate with the presence of a 6-hydroxyl group in Lb. Importantly, Pt1 and Pt2 exhibited higher safety in vivo and more effective inhibitory effects on tumor growth in the HCT-8 and NCI-H460 xenograft mouse model, compared with cisplatin. Taken together, these mechanistic insights indicate that both Pt1 and Pt2 display low toxicity and could be novel anticancer drug candidates.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION

Disclosed herein are compounds that target SMARCA2 and SMARCA4, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Structure-based design, synthesis, PPAR-γ activation, and molecular docking of N-substituted phthalimides

N-substituted phthalimides showed peroxisome proliferator-activated receptors-γ activation in rat liver epithelial Ac2F cells in our previous study. In order to explore better peroxisome proliferator-activated receptors-γ agonists, new N-substituted phthalimide derivatives were designed and synthesized based on a pharmacophore study of natural peroxisome proliferator-activated receptors-γ agonist paecilocin A and synthetic leads. Peroxisome proliferator-activated receptors-γ activation by the new derivatives was evaluated using rat liver epithelial Ac2F cells at a concentration of 10 μM (same as previous study). All the new derivatives showed comparable or better activities than that of rosiglitazone, in which 3-hydroxy-N-(p-methoxy-phenethyl) phthalimide (compound 6) appeared as the best. Molecular docking suggested that the free hydroxyl group on the phthalimide head, a proper hydrophobic tail including a phenyl linker, were beneficial for peroxisome proliferator-activated receptors-γ activation. These N-substituted phthalimide derivatives are valuable as scaffolds for new peroxisome proliferator-activated receptors-γ agonists.